Suppr超能文献

长链非编码 RNA FOXP4-AS1 预测肝细胞癌不良预后并调节增殖和侵袭。

Long Noncoding RNA FOXP4-AS1 Predicts Unfavourable Prognosis and Regulates Proliferation and Invasion in Hepatocellular Carcinoma.

机构信息

Department of Ultrasound, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, China.

出版信息

Biomed Res Int. 2021 Feb 1;2021:8850656. doi: 10.1155/2021/8850656. eCollection 2021.

Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer that has a high level of morbidity and mortality. Long noncoding RNA (lncRNA) is a novel regulatory factor of tumour proliferation, apoptosis, and metastasis. Our previous studies indicated that lncRNA FOXP4-AS1 is a functional oncogene in HCC; thus, this study is aimed at further evaluating the clinical and biological function of FOXP4-AS1 in HCC. . First, we detected the expression of FOXP4-AS1 in HCC tissues and paracarcinoma normal tissues by qRT-PCR. Second, the prognostic effects of FOXP4-AS1 in patients with HCC were analysed in a training group and a verification group. Subsequently, to investigate the biological effects of FOXP4-AS1 on HCC cells, downexpression tests were further conducted.

RESULTS

The expression of FOXP4-AS1 was higher in HCC tissues than adjacent nontumourous tissues, whereas the low expression of FOXP4-AS1 was correlated with optimistic treatment outcomes, which suggested that FOXP4-AS1 may be an independent prognostic biomarker for HCC. Moreover, the downregulation of FOXP4-AS1 significantly reduced the cell proliferation and clonal abilities and inhibited the invasion, migration, and angiogenesis of hepatoma cells ( < 0.05).

CONCLUSION

These results revealed the clinical significance and biological function of FOXP4-AS1 in HCC development, which may provide a new direction for finding therapeutic targets and potential prognostic biomarkers of HCC.

摘要

背景

肝细胞癌(HCC)是最常见的原发性肝癌,发病率和死亡率都很高。长链非编码 RNA(lncRNA)是肿瘤增殖、凋亡和转移的新型调节因子。我们之前的研究表明,lncRNA FOXP4-AS1 是 HCC 中的一种功能性癌基因;因此,本研究旨在进一步评估 FOXP4-AS1 在 HCC 中的临床和生物学功能。首先,我们通过 qRT-PCR 检测 HCC 组织和癌旁正常组织中 FOXP4-AS1 的表达。其次,在训练组和验证组中分析 FOXP4-AS1 对 HCC 患者的预后影响。随后,为了研究 FOXP4-AS1 对 HCC 细胞的生物学影响,我们进一步进行了下调实验。

结果

FOXP4-AS1 在 HCC 组织中的表达高于相邻非肿瘤组织,而 FOXP4-AS1 的低表达与乐观的治疗结果相关,这表明 FOXP4-AS1 可能是 HCC 的独立预后生物标志物。此外,下调 FOXP4-AS1 显著降低了肝癌细胞的增殖和克隆能力,并抑制了肝癌细胞的侵袭、迁移和血管生成(<0.05)。

结论

这些结果揭示了 FOXP4-AS1 在 HCC 发展中的临床意义和生物学功能,为寻找 HCC 的治疗靶点和潜在预后生物标志物提供了新的方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21e/7870313/370dd231af74/BMRI2021-8850656.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验